Friday, May 17, 2019 5:46:03 PM
it's a leap of faith.
You either believe in lironlimab, or you don't.
LM, I do agree here - and not trding's "creative math", which puts value on imaginary previously out of the money Warrants.
Of course: Now the Warrants are very valuable, but that's only due to the effectively lowered strike.
Why is it important to believe in a company & stock?
We can do all the DD we want and it might be helpful or not,
but surely we cannot know the inside details of what is going on.
Quite often, DD helps to see the financial negative - rarely the semantic positive turnaround, which is not in the filings.
Here: It is sort of split in half.
Q: Would many like the same offerings as Warrant holders?
A: Yes trding, of course.
Q: Would it be fair?
A: Probably not, b/c they have not invested higher.
Q: Does it financially change the fact that they get the new shares at 26.67c?
A: No (o8>
Q: In the end, will it help CYDY to have gathered the cash?
A: Sure, a bit desperate maybe - no licensing deal etc, but maybe market forgives the new 213M shares max - valuation does not though. Sometimes you have to bite into the lemon to overcome tough times.
Q: Will the stock touch the 26.67c strike price?
A: Nobody knows.
So whatever happens from here, let's see and watch.
- GvHD trial Dec'19 https://clinicaltrials.gov/ct2/show/NCT02737306?term=Cytodyn&draw=1&rank=7
- TNBC trial 1Q20 via https://clinicaltrials.gov/ct2/show/NCT03838367?term=Cytodyn&rank=3
EDIT: Interim result upfront ...
- New Pivotal Mono: No population size given yet, waiting for IND
Monday you may ask whether the 700mg safety data will be completed via the new pivotal Mono trial, then we all will have a better understanding about the Combo BLA schedule.
Dec'19 - March'20 has at least two strong events GvHD + TNBC.
Maybe HIV-1 Combo BLA progress as well.
Four month full of events?
Stock needs it.
Have a great weekend all - and LM, thank you and I wish you also good luck.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
